About MS Views and News

Within this blog you will find thousands of valuable MS related articles and resources which will enable you to learn and feel empowered with key Multiple Sclerosis information.

Please Visit our Website: www.msvn.org and our Social media platforms: Facebook, Twitter, and Instagram. Each providing knowledge for those affected by MS. *

From the comfort of your home, you can join us for our VIRTUAL MS events. To learn more of these virtual events please subscribe here.

Be empowered with MS news. CLICK HERE -to Subscribe forThe MS BEACON eNewsletter

Plus, learn from the MS Views and News Learning Channel on YouTube: www.youtube.com/msviewsandnews:


Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Saturday, September 15, 2018

Can Medical Marijuana Ease MS Symptoms?

Medical marijuana is any part of the marijuana plant that you use to treat health problems. People use it to get relief from their symptoms, not to try to get high.
Most marijuana that's sold legally as medicine has the same ingredients as the kind that people use for pleasure. But some medical marijuana is specially grown to have less of the chemicals that cause feelings of euphoria.
medical marijuana plant

Marijuana plants have multiple chemicals, known as cannabinoids. The two main ones are THC and CBD. THC gives some of the pleasurable effects that pot smokers are looking for, but it also has some effects that may treat medical problems.
Some research suggests that CBD may be helpful for some health issues, but it doesn't cause you to get high.
Read more by clicking here (WebMD)


Join us on October 27th at the Renaissance Hotel in Plantation, Fla. as we seek financial support for the launch of our:
Reaching Rural America Project

 Help support our mission to provide MS Patients and Care Partners with Multiple Sclerosis educational programs and resources in underserved communities. 

Come enjoy an evening beginning with cocktail hour & silent auction.
Followed by dinner, award presentations, a musical performance, photo booth fun and so much more.

Friday, September 14, 2018

Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with relapsing multiple sclerosis

Sep 13, 2018


To receive MS news and information via e-mail, Please Click here 

Tuesday, September 11, 2018

Managing PPMS and Your Career

Having primary progressive multiple sclerosis (PPMS) can warrant adjustments to various aspects of your life, including your job. In severe cases, PPMS can make it challenging to work. According to an article in the International Journal of MS Care, PPMS causes a higher likelihood of not being able to work compared with other forms of MS.
However, this doesn’t necessarily mean you have to stop working altogether. Here are the answers to some of the most common work-related questions about PPMS.


To receive MS news and information via e-mail, Please Click here 

CLICK BOX to SUBSCRIBE to our MS Learning Channel on YouTube: 

Monday, September 10, 2018

U.S. Court of Appeals for the Federal Circuit Upholds District Court’s Decision to Invalidate AMPYRA® (dalfampridine) Patents

ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the United States Court of Appeals for the Federal Circuit, by a 2-1 vote, has upheld the United States District Court for the District of Delaware’s decision to invalidate four AMPYRA patents. This decision affirms the District Court’s ruling on March 31, 2017 invalidating U.S. Patent Nos. 8,663,685 (the ‘685 patent), 8,007,826 (the ‘826 patent), 8,440,703 (the ‘703 patent), and 8,354,437 (the ‘437 patent) pertaining to AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg. Acorda’s U.S. Patent No. 5,540,938 (the ‘938 patent), previously upheld by the District Court, expired on July 30, 2018.
“We are disappointed by the Court’s decision, as we continue to believe that our AMPYRA patents reflected true invention and were valid. We are reviewing the decision and will consider future options, including the possibility of a further appeal,” said Ron Cohen, M.D., Acorda's President and CEO. “Following the Court’s original decision in 2017, we prepared a contingency plan that we could face generic competition, implementing a comprehensive corporate restructuring and bolstering our balance sheet. As a result, we are well-capitalized and fully focused on the potential launch of INBRIJA for Parkinson’s disease.”